Day Gain | ||
Gain | ||
Market Val | ||
Costs | ||
Cash | ||
Portfolio | ||
Realized | ||
Dividend |
Date | For | Estimate | Reported | Surprise | surprise % |
---|---|---|---|---|---|
2024-04-30 | 2024-03 | 2.53 | N/A | N/A | N/A |
2024-02-06 | 2023-12 | 2.47 | 2.49 | 0.02 | 0.81% |
2023-11-02 | 2023-09 | -0.08 | 0.1 | 0.18 | 225.00% |
2023-08-08 | 2023-06 | 1.98 | 2.11 | 0.13 | 6.57% |
2023-04-27 | 2023-03 | 1.73 | 1.62 | -0.11 | -6.36% |
2023-02-02 | 2022-12 | 1.83 | 2.09 | 0.26 | 14.21% |
Date | Firm | Action | From | To |
---|---|---|---|---|
2023-10-10 | Morgan Stanley | Upgrade | Overweight | Overweight |
2023-10-08 | Wells Fargo | Upgrade | Overweight | Overweight |
2023-10-08 | Cantor Fitzgerald | Upgrade | Overweight | Overweight |
2023-10-01 | Cantor Fitzgerald | Upgrade | Overweight | Overweight |
2023-09-04 | Cantor Fitzgerald | Upgrade | Overweight | Overweight |
2023-09-04 | Morgan Stanley | Upgrade | Overweight | Overweight |
Date | Name | Relation | Quantity | Description |
---|---|---|---|---|
2024-04-14 | ALVAREZ RALPH | Director | 54.03K | Stock Award(Grant) |
2024-02-11 | HAKIM ANAT | General Counsel | 30.48K | Stock Award(Grant) |
2024-04-14 | HEDLEY MARY LYNNE | Director | 1.58K | Stock Award(Grant) |
2024-04-14 | JOHNSON KIMBERLY H | Director | 2.63K | Stock Award(Grant) |
2024-02-15 | LILLY ENDOWMENT, INC. | Beneficial Owner of more than 10% of a Class of Security | 98.90M | Sale |
2024-04-14 | LUCIANO JUAN R | Director | 15.68K | Stock Award(Grant) |
Report Date | Organization | Position | Value | Percentage |
---|---|---|---|---|
2023-09-29 | Lilly Endowment, Inc | 99.98M | 53.70B | 10.53% |
2023-06-29 | Vanguard Group Inc | 69.92M | 32.79B | 7.37% |
2023-06-29 | Blackrock Inc. | 64.45M | 30.23B | 6.79% |
2023-06-29 | PNC Financial Services Group, Inc. | 51.87M | 24.33B | 5.46% |
2023-06-29 | State Street Corporation | 33.88M | 15.89B | 3.57% |
2023-06-29 | FMR, LLC | 32.80M | 15.38B | 3.46% |
Report Date | Organization | Position | Value | Percentage |
---|---|---|---|---|
2023-06-29 | Vanguard Total Stock Market Index Fund | 26.65M | 12.50B | 2.81% |
2023-06-29 | Vanguard 500 Index Fund | 18.76M | 8.80B | 1.98% |
2023-06-29 | Vanguard/Primecap Fund | 13.35M | 6.26B | 1.41% |
2023-05-30 | Fidelity 500 Index Fund | 8.83M | 3.79B | 0.93% |
2023-08-30 | SPDR S&P 500 ETF Trust | 8.68M | 4.81B | 0.91% |
2023-08-30 | iShares Core S&P 500 ETF | 7.37M | 4.08B | 0.78% |
Dividend | Date |
---|---|
1.3 | 2024-02-15 |
1.3 | 2024-02-14 |
1.13 | 2023-11-14 |
1.13 | 2023-09-08 |
1.13 | 2023-08-14 |
1.13 | 2023-05-12 |
Split | Date |
---|---|
2 : 1 | 1997-10-16 |
2 : 1 | 1995-12-21 |
2 : 1 | 1989-05-01 |
2 : 1 | 1986-01-30 |
-
-
Eli Lilly to enter licence agreement for novel CX3CR1 inhibitor, undertake responsibility for clinical development, commercialization?
-
Sorrento therapeutics
-
Less dose! 10times as potent ! Don’t need infusion
-
Sorrento is better
-
-
-
My hospital is pumping this med $LLY gonna be a billionaire beat
-
They know Sorrento is better and less dosage
-
But $SRNE has the most Potent cocktail
-
Hmmmm something is going to blow
-
Regeneron already has rights to it
-
Maybe lily owns the bar but sell srne?
-
But $SRNE has a better cocktail???????
-
$SRNE is a better product
-
-
-
-
$SAVA - A second opinion
*
If you have been following Cassava and their Alzheimers drug PTI-125, you will know that 1 of 2 trial endpoints was not recently met, sending the stock down almost 80%. But, I think the exodus was premature. Here is why:Per the companys press release, one endpoint WAS MET:
A secondary endpoint of CSF levels of IL1-beta, a core biomarker of neuroinflammation from baseline to day 28, was met, Cassava said. The drug was also found to be safe and well-tolerated.Per NIH, neuro inflammation is the CORE issue with Alzheimers:
Inflammation in Alzheimer's disease (AD) has emerged as a central pathology that likely plays a role in onset and progression of the disease
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6214864/Cycling back to Cassavas press release, they state:
CSF levels of IL1-beta, a core biomarker of neuroinflammation ... was met
To reiterate the NIH definition, Neuro Inflammation is core to the onset and progression of Alzheimers. At some point, Cassava IS going to cycle back around to the secondary endpoint (neuro inflammation), and realize that ALONE constitutes an ALZHEIMER DRUG THAT WORKS.
In this case, traders were SO tuned into the word miss that they MISSED something EXTREMELY IMPORTANT -> The efficacy of PTI-125 towards Neuro Inflammation, in Alzheimers (ALONE), makes it A BLOCKBUSTER DRUG!
-
$SAVA - A second opinion
*
If you have been following Cassava and their Alzheimers drug PTI-125, you will know that 1 of 2 endpoints was not recently met, sending the stock down almost 80%. But, I think the exodus was premature. Here is why:Per the companys press release, one endpoint WAS MET:
A secondary endpoint of CSF levels of IL1-beta, a core biomarker of neuroinflammation from baseline to day 28, was met, Cassava said. The drug was also found to be safe and well-tolerated.Per NIH, here is the CORE issue with
Alzheimers:
Inflammation in Alzheimer's disease (AD) has emerged as a central pathology that likely plays a role in onset and progression of the disease
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6214864/Cycling back to Cassavas press release, they state:
CSF levels of IL1-beta, a core biomarker of neuroinflammation ... was met
To reiterate the NIH definition, Neuro Inflammation is core to the onset and progression of Alzheimers. At some point, Cassava IS going to cycle back around to the secondary endpoint (neuro inflammation), and realize that ALONE constitutes an ALZHEIMER DRUG THAT WORKS.
In this case, traders were SO tuned into the word miss that they MISSED something EXTREMELY IMPORTANT. That the efficacy of PTI-125 towards Neuro Inflammation, in Alzheimers (ALONE), makes it A BLOCKBUSTER DRUG!
-
What You Need To Know Ahead of Eli Lilly's Earnings Report Tuesday
investopedia.com • -
LLY June 7th Options Begin Trading
news.google.com • -
MSN
news.google.com • -
Analysts Set Eli Lilly and Company (NYSE:LLY) Target Price at $728.05
news.google.com • -
Eli Lilly and Company (NYSE:LLY) Stock Price Down 1.3%
news.google.com • -
Eli Lilly & Co. stock outperforms competitors despite losses on the day
news.google.com • -
LLY (Eli Lilly and Co) Book Value per Share
news.google.com • -
Is Eli Lilly Stock A Buy After Weight-Loss Win In Sleep Apnea?
news.google.com • -
Don't Miss Out! 3 Top-Tier Blue-Chip Growth Stocks for Your Must-Buy List
investorplace.com • -
Eli Lilly & Company (LLY) Should Continue Bullish Rally
news.google.com • -
LLY vs. JNJ: Which Big Pharma Stock Is Better?- TipRanks
news.google.com • -
Which Companies Will Join the Trillion-Dollar Team in 2024? Our 3 Best Guesses
investorplace.com • -
Should Eli Lilly (LLY) Be in Your Portfolio Ahead of Q1 Earnings?
news.google.com • -
Should Eli Lilly (LLY) Be in Your Portfolio Ahead of Q1 Earnings?
news.google.com • -
Going Into Earnings, Is Eli Lilly Stock a Buy, a Sell, or Fairly Valued?
news.google.com • -
Eli Lilly (LLY) Reports Next Week: Wall Street Expects Earnings Growth
news.google.com • -
Eli Lilly and Company (LLY) to Release Quarterly Earnings on Tuesday
news.google.com • -
Eli Lilly (LLY) Advances But Underperforms Market: Key Facts
news.google.com • -
Eli Lilly (NYSE:LLY) Notches Up on New Manufacturing Plans- TipRanks
news.google.com • -
7 High-Flying Stocks That Are Majorly Overdue for a Pullback
investorplace.com • -
What You Can Learn From Eli Lilly and Company's (NYSE:LLY) P/S
news.google.com • -
Wegovy vs. Zepbound: Who Wins the Battle of the GLP-1 Drugs?
marketbeat.com • -
11 Hot Growth Stocks To Buy Right Now
news.google.com • -
Bearish on SMCI & Bullish on LLY, NFLX
youtube.com • -
Strong Buy Alert: 7 No-Brainer Stocks to Scoop Up Now
investorplace.com • -
Big pharma: cautious optimism ahead of earnings season - analysts
proactiveinvestors.com • -
Eli Lilly's Chart Gets Another Boost from Obesity Drug
youtube.com • -
Eli Lilly's Weight-Loss Treatment Found To Help Those With Sleep Apnea
investopedia.com • -
Eli Lilly's weight-loss drug Zepbound might help cure your sleep apnea
fastcompany.com • -
Eli Lilly Stock Pops on Drug Efficacy for Sleep Apnea
schaeffersresearch.com • -
Eli Lilly's weightloss drug helps reduce sleep apnoea
proactiveinvestors.com • -
Shed the Fat, Gain the Profits: 3 Weight-Loss Stocks to Own Until 2027
investorplace.com • -
3 Growth Stocks with Even Greater Potential Than the Magnificent 7
investorplace.com • -
Why Eli Lilly Stock Topped the Market Today
fool.com • -
The 3 Best Healthcare Stocks to Buy in April 2024
investorplace.com • -
Biotech's Next Gold Rush: Weight-Loss Drugs
youtube.com • -
5 Healthcare Stocks to Buy for 2024
investorplace.com •